- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
		
	   		
	   		    
                    
                   	
                   	    6 result(s) found for: CD59.
                    
                
			
   			
		
		Displaying page 1 of 1.
	
	
| EudraCT Number: 2017-000169-60 | Sponsor Protocol Number: CA209-755 | Start Date*: 2017-05-23 | |||||||||||
| Sponsor Name:VU University Medical Center | |||||||||||||
| Full Title: A phase 2 study of nivolumab combined with daratumumab with or without low dose cyclophosphamide in relapsed/refractory multiple myeloma | |||||||||||||
| Medical condition: relapsed/refractory multiple myeloma | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001587-13 | Sponsor Protocol Number: RC21_0169 | Start Date*: 2021-10-01 | 
| Sponsor Name:CHU de Nantes | ||
| Full Title: A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse. | ||
| Medical condition: Elderly patients with multiple myeloma at first relapse | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-004268-36 | Sponsor Protocol Number: APL2-302 | Start Date*: 2018-10-01 | |||||||||||
| Sponsor Name:Apellis Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
| Medical condition: PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic epis... | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed) FR (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003862-10 | Sponsor Protocol Number: Dara-Atra | Start Date*: 2016-04-01 | |||||||||||
| Sponsor Name:VU University Medical Center | |||||||||||||
| Full Title: A phase 1 and phase 2 study of daratumumab in combination with all-trans retinoic acid in relapsed/refractory multiple myeloma | |||||||||||||
| Medical condition: relapsed/refractory multiple myeloma | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002431-30 | Sponsor Protocol Number: GT005-03 | Start Date*: 2020-10-21 | |||||||||||
| Sponsor Name:Gyroscope Therapeutics | |||||||||||||
| Full Title: HORIZON: A Phase II, open-label, outcomes-assessor masked, multicentre, randomised,controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal inj... | |||||||||||||
| Medical condition: Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The prima... | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-006163-31 | Sponsor Protocol Number: Hx-CD20-406 | Start Date*: 2006-05-16 | |||||||||||
| Sponsor Name:Genmab A/S | |||||||||||||
| Full Title: A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alem... | |||||||||||||
| Medical condition: B-cell Chronic Lymphocytic Leukemia | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) IT (Completed) BE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
 .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
 Query did not match any studies.
    	Query did not match any studies.
     
				
